Page last updated: 2024-11-08

carboxyebselen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carboxyebselen: a nitric oxide synthase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID192654
CHEMBL ID3655715
SCHEMBL ID16010218
MeSH IDM0234377

Synonyms (19)

Synonym
4-(3-oxo-1,2-benzoselenazol-2(3h)-yl)benzoic acid
4-(3-oxo-1,2-benzoselenazol-2-yl)benzoic acid
nsc-639765
nsc639765
carboxyebselen
153871-75-1
2-(4-carboxyphenyl)-1,2-benzisoselenazol-3(2h)-one
carboxy-ebselen
carboxyl-ebselen
hooc-ebs
bdbm106943
us8592468, ebse10
SCHEMBL16010218
CHEMBL3655715
DTXSID80165469
CS-0201496
HY-139448
AKOS040756885
4-(3-oxobenzo[d][1,2]selenazol-2(3h)-yl)benzoic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Drug combination assays indicated that these derivatives exhibited synergistic antimicrobial activity when used along with meropenem, effectively restoring the activity of carbapenems against the resistant strains tested in a Galleria mellonella larvae in vivo infection model."( Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
Chan, EWC; Chan, KF; Chan, TH; Chen, S; Cheng, Q; Gao, W; Jin, WB; Leung, YC; Qi, XL; Wong, KY; Xu, C; Zheng, Z, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.13000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.13000.00022.45859.9600AID1805801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1822748Antifungal activity against Candida albicans SC5314 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679970Growth inhibition of Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 incubated for overnight by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1822751Antifungal activity against fluconazole resistant Candida albicans 904 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1434671Antitrypanosomal activity against Trypanosoma brucei 427 bloodstream forms after 72 hrs by CellTiter-Blue fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1679971Potentiation of meropenem-induced antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as bacterial growth inhibition by measuring meropenem MIC incubated for overnight by CLSI protocol based assa2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1822756Inhibition of wild type Candida albicans Fructose-1,6-Bisphosphate Aldolase transfected in Escherichia coli BL21 (DE3) incubated for 3 mins in presence of NADH by spectrophotometric analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1679969Synergistic antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as fractional inhibitory concentration index in presence of meropenem incubated for overnight by CLSI protocol based assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1434670Antitrypanosomal activity against Trypanosoma brucei 427 bloodstream forms at 10 uM after 72 hrs by CellTiter-Blue fluorescence assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1822750Antifungal activity against fluconazole resistant Candida albicans 7781 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1434669Inhibition of recombinant Trypanosoma brucei His6-tagged HK1 expressed in Escherichia coli M15(pREP) harboring pQE30 using glucose as substrate by spectrophotometric based glucose 6-phosphate dehydrogenase enzyme coupled assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1434668Inhibition of recombinant Trypanosoma brucei His6-tagged HK1 expressed in Escherichia coli M15(pREP) harboring pQE30 at 10 uM using glucose as substrate by spectrophotometric based glucose 6-phosphate dehydrogenase enzyme coupled assay2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Evaluation of substituted ebselen derivatives as potential trypanocidal agents.
AID1679968Synergistic antibacterial activity against Escherichia coli TG1 transformed with IncX3 plasmid expressing blaNDM-1 assessed as ratio of negative logarithm of fractional inhibitory concentration index to non-hydrogen atom in presence of meropenem incubated2018European journal of medicinal chemistry, Jul-15, Volume: 155Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.
AID1822749Antifungal activity against fluconazole resistant Candida albicans 103 incubated for 48 hrs by CLSI based broth microdilution method2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.62 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]